EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer
NCT02183870
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Patients with adenocarcinoma of the lung that is locally advanced or metastatic independent from the number of prior lines of therapy, i.e. including non-pretreated patients (UICC stage IIIB or IV)
- Positive for ROS1 translocation by central FISH-testing
- Ability to swallow pills
- Age > 18 years
- ECOG performance status 0 to 2
- Life expectancy of at least 12 weeks
- Disease measurable per Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1)
- Any prior treatment (chemotherapy, radiation or surgery) must have been completed at least 2 weeks prior to initiation of study medication
- Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 14 days prior to screening:
- Hemoglobin ≥ 8.0 g/dL
- Absolute neutrophil count (ANC) ≥ 1,000 /mm3
- Platelet count ≥ 50 000/µL
- Total bilirubin ≤ 2 x upper limit of normal (ULN)
- Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatase (AP) ≤ 2,5 x ULN or ≤ 5 x ULN in case of liver involvement
- PT-INR/PTT ≤ 1.5 x ULN
- Serum creatinine ≤ 2 times ULN
- Calculated creatinine clearance (CLcr) ≥ 40 ml/min (Cockcroft-Gault formula)
- Written informed consent
- Negative serum pregnancy test within 3 days prior to start of dosing premenopausal women. Women of non-childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for ≥ 1 year.
Fertile men and women must have an effective method of contraception during treatment and for at least 3 months after completion of treatment as directed by their physician. Effective methods of contraception result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence where lifestyle of the patient ensures compliance (Periodic abstinence and withdrawal are not acceptable methods of contraception).
- Previous treatment with specific ALK or ROS1 inhibitors
- Current treatment within another therapeutic clinical trial
- Other history of ongoing malignancy that would potentially interfere with the
interpretation of efficacy (early stage or chronic disease is allowed if not requiring
active therapy or intervention and being under control)
- Pregnancy or breastfeeding
- Use of drugs or foods that are known potent CYP3A4 inhibitors, including but not
limited to atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole,
nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin,
voriconazole and grapefruit or grapefruit juice
- Use of drugs that are known potent CYP3A4 inducers, including but not limited to
carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, and St. John's wort
- Use of drugs that are CYP3A4 substrates with narrow therapeutic indices, including but
not limited to dihydroergotamine, ergotamine, pimozide, astemizole, cisapride, and
terfenadine
- Active CNS metastases. Patients with brain metastasis are eligible if asymptomatic for
≥ 14 days before starting study medication and off corticosteroids.
- History of or known carcinomatous meningitis or leptomeningeal disease
- Known diagnosis of HIV, active hepatitis B and/or C (testing is not mandatory)
- Any person being in an institution on assignment of the respective authority against
his/her own will
- Any medical, mental or psychological condition which in the opinion of the
investigator would not permit the patient to complete the study or understand the
patient information
- Ongoing cardiac dysrhythmias of CTCAE grade ≥2, uncontrolled atrial fibrillation of
any grade or QTcF interval > 470ms
- Patients with known interstitial fibrosis or interstitial lung disease
- Any of the following within 3 months prior to first crizotinib administration:
Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure,
cerebrovascular accident or transient ischemic attack
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Heidelberg, Baden-Würtemberg
- Frankfurt a.M., Hessen
- Großhansdorf, Schleswig-Holstein
- Berlin,
- Cologne,
- Tübingen,
- A Coruna,
- Alicante,
- Barcelona,
- Barcelona,
- Las Palmas de Gran Canaria,
- Madrid,
- Majadahonda,
- Malaga,
- Palma de Mallorca,
- Sevilla,
- Valencia,
- Basel,
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer | |||
| Official Title ICMJE | EUCROSS: A Phase II Trial to Evaluate Efficacy and Safety of Crizotinib Treatment in Advanced Adenocarcinoma of the Lung Harbouring ROS1 Translocations | |||
| Brief Summary | EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with 250mg crizotinib bid until progression or intolerable toxicity. | |||
| Detailed Description | EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. In individual treatment attempts and an ongoing phase I trial crizotinib has shown remarkable effects on this selected subgroup of lung cancer patients. Crizotinib is a tyrosine kinase inhibitor, blocking the catalytic activity of rearranged ALK and ROS1 as well as MET. The patients eligible for the trial will be treated with 250mg crizotinib twice-daily. Tumor response to treatment will be assessed every 6 weeks by CT or MRI scans. In case of progression treatment beyond may be conducted if clinically indicated. To identify mechanisms of resistance to crizotinib treatment, an optional re-biopsy may be performed in these cases and fresh frozen tumor material will analyzed at the University of Cologne. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 2 | |||
| Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE |
| |||
| Intervention ICMJE | Drug: Crizotinib
250mg crizotinib bid until end of treatment Other Name: Xalkori | |||
| Study Arms ICMJE | Experimental: Crizotinib
Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated. Intervention: Drug: Crizotinib | |||
| Publications * |
| |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Active, not recruiting | |||
| Estimated Enrollment ICMJE | 30 | |||
| Original Estimated Enrollment ICMJE | Same as current | |||
| Estimated Study Completion Date ICMJE | January 2020 | |||
| Actual Primary Completion Date | April 2017 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Fertile men and women must have an effective method of contraception during treatment and for at least 3 months after completion of treatment as directed by their physician. Effective methods of contraception result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices). At the discretion of the investigator, acceptable methods of contraception may include total abstinence where lifestyle of the patient ensures compliance (Periodic abstinence and withdrawal are not acceptable methods of contraception). Exclusion Criteria:
Myocardial infarction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack | |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | Germany, Spain, Switzerland | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT02183870 | |||
| Other Study ID Numbers ICMJE | EUCROSS 2013-002737-38 ( EudraCT Number ) DRKS00005409 ( Other Identifier: DRKS ) | |||
| Has Data Monitoring Committee | Yes | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Prof. Dr. Juergen Wolf, University of Cologne | |||
| Study Sponsor ICMJE | University of Cologne | |||
| Collaborators ICMJE |
| |||
| Investigators ICMJE |
| |||
| PRS Account | University of Cologne | |||
| Verification Date | July 2019 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||